Analysis for SYK

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues grew from about $5.42B (2024-Q1) to $6.02B (2026-Q1), roughly an 11% rise. Net income oscillated but remained in the high hundreds of millions, ending at $745M in 2026-Q1 after peaking around $849M–$884M in 2025. The trajectory shows steady top-line expansion with earnings momentum fluctuating, implying improving scale but uneven quarterly profitability.

💰 Margins & Cash Flow

Gross margins stayed in the mid-60s percent; operating margins ranged from the high teens to the low-20s, with a peak in 2025-Q4. Net cash from operating activities was generally positive, but cash flows were volatile; 2026-Q1 saw a negative net cash flow driven by investing/financing activity, totaling about -$1.13B.

🛡️ Balance Sheet & Liquidity

Assets run near $46–47B with liabilities around $24–28B, yielding a solid equity base (~$20–22B). Current assets comfortably cover current liabilities, with a typical current ratio of roughly 1.6–2.1x, indicating liquidity resilience even as quarterly cash flow fluctuates.

⚠️ Key Drivers & Risks

• Drivers: Ongoing demand in orthopedic/reconstructive devices; geographic mix and procedure volumes supporting revenue stability.
• Risks: Volatility in elective-procedure demand and reimbursement/pricing pressures; cash flow sensitivity to financing/investing decisions and macro cycles.